Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-20T01:36:24.022Z Has data issue: false hasContentIssue false
  • English
  • Français

Increased Plasma Catecholamines in Patients with Friedreich’s Ataxia

Published online by Cambridge University Press:  18 September 2015

A. Pasternac ,
P. Wagniart ,
R. Olivenstein ,
R. Petitclerc ,
R. Krol ,
E. Andermann ,
S. Melancon ,
G. Geoffroy ,
J. de Champlain  and
A. Barbeau
A. Pasternac
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
P. Wagniart
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
R. Olivenstein
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
R. Petitclerc
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
R. Krol
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
E. Andermann
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
S. Melancon
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
G. Geoffroy
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
J. de Champlain
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
A. Barbeau*
Affiliation:
Department of Medicine of the Montreal Heart Institute, and the Clinical Research Institute, Departments of Medicine and Physiology. University of Montreal and the Department of Neurogenetics, the Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada
*
Clinical Research Institute of Montreal, 110 West Pine Avenue West, Montréal, Quebec, Canada H2W 1R7
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We studied free plasma catecholamines in 23 patients with Friedreich’s ataxia, having a mean age of 22 ± 9.6 (SD) years. Conjugated catecholamines were also studied in 10 patients. Mean plasma norepinephrine and epinephrine were significantly higher than controls both in the supine and standing positions. In total 15 out of 23 patients (65%) had increased free and/or conjugated plasma catecholamines. The increase in plasma catecholamines was more marked in patients with severe neuromotor impairment. Among the patients with left ventricular concentric hypertrophy (wall thickness >12 mm), only 3 had no demonstrable sympathetic hyperfunction.

Since the high local concentrations of norepinephrine at the site of release from sympathetic nerve terminals may serve as a trigger for the hypertrophic response of the myocardial cell, it is suggested that early pharmacological intervention could prevent or limit the cardiomyopathic process or its clinical consequences.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 9 , Issue 2 , May 1982 , pp. 195 - 203
Copyright
Copyright © Canadian Neurological Sciences Federation 1982

References

REFERENCES

Alousi, A.A. and Beards, J.A. (1972). Catecholamine, protein and RNA content in advanced congestive heart failure in the Syrian hamster. In: Recent Advances in Studies on Cardiac Structure and Metabolism. Bajusz, E. and Rona, G., editors. University Park Press, Baltimore. Vol. 1, pp. 279–288.Google Scholar
Angelakos, E.T.Carballo, L.C., Daniels, J.B., King, M.B. and Bajusz, E. (1972). Adrenergic neurohumors in the heart of hamsters with hereditary myopathy during cardiac hypertrophy and failure. In: Recent Advances in Studies on Cardiac Structure and Metabolism. Bajusz, E. and Rona, G., editors. University Park Press, Baltimore. Vol. 1, pp. 288–299.Google Scholar
Angelakos, E.T.King, M.B. and Carballo, L. (1973). Cardiac adrenergic innervation in hamsters with hereditary myocardiopathy: chemical and histochemical studies. In: Recent Advances in Studies on Cardiac Structure and Metabolism. Bajusz, E. and Rona, G., editors. University Park Press, Baltimore. Vol. 2, pp. 519–531.Google Scholar
Azari, J., Reiusine, T., Barbeau, A., Yamamura, H.I. and Huxtable, R. (1979). The Syrian Golden hamster: A model for the cardiomyopathy of Friedreich’s ataxia. Can. J. Neurol. Sci. 6: 223–226.CrossRefGoogle Scholar
Bajusz, E., Homburger, F., Baker, J.R. and Opie, L.H. (1966). The heart muscle in muscular dystrophy with special reference to involvement of the cardiovascular system in the hereditary myopathy of the hamster. Ann. N.Y. Acad. Sci. 138:213–229.CrossRefGoogle Scholar
Cohen, J. (1974). Role of endocrine factors in the pathogenesis of cardiac hypertrophy. Circ. Res. 35 (Suppl II): 49–57.Google ScholarPubMed
Cote, M., Davignon, A., Peckodrouin, K., Solignac, A., Geoffroy, G., Lemieux, B. and Barbeau, A. (1976). Cardiological signs and symptoms in Friedreich’s ataxia. Can. J. Neurol. Sci. 3:319–321.CrossRefGoogle ScholarPubMed
Davies, A.O., De Lean, A. and Lefkowitz, R.J. (1981). Myocardial beta-adrenergic receptors from adrenalectomized rats: impaired formation of high-affinity agonist-receptor complexes. Endocrinology 108:720–722.CrossRefGoogle ScholarPubMed
Goldstein, D.S. (1981). Plasma norepinephrine activity in clinical cardiology. Am. J. Cardiol. 48: 1147–1154.CrossRefGoogle ScholarPubMed
Goodwin, J.F. (1974). Prospects and predictions for the cardiomyopathies. Circulation 50:210–219.CrossRefGoogle ScholarPubMed
Goodwin, J.F. and Krikler, D.M. (1976). Hypothesis: arrhythmia as a cause of sudden death in hypertrophic cardiomyopathy. Lancet 2: 937–940.CrossRefGoogle Scholar
Gottdiener, J.S., Hawley, R.J.. Marón, B.J., Bertorini, T.F. and Engel, W.K. (1979). Hypertrophic cardiomyopathy in Friedreich’s ataxia. Circulation 60 (Suppl II): 242.Google Scholar
Hartman, J.M. and Booth, R.W. (1960). Friedreich’s ataxia: a neurocardiac disease. Am. Heart J. 60: 716–720.CrossRefGoogle ScholarPubMed
Johnson, G.A., Baker, C.A. and Smith, R.T. (1980). Radioenzymatic assay of sulfate conjugates of catecholamines and dopa in plasma. Life Sci. 26: 1591–1598.CrossRefGoogle ScholarPubMed
Kafka, M., Tallman, J.F., Smith, C.C. and Costa, J.L. (1977). Alpha-adrenergic receptors in human platelets. Life Sci. 21: 1429–1438.CrossRefGoogle ScholarPubMed
Karliner, J.S., Alabaster, C., Stephens, H., Barnes, P. and Dollery, C. (1981). Enhanced noradrenaline response in cardiomyopathic hamsters: possible relation to changes in adrenoceptors studied by radioligand binding. Cardiovasc. Res. 15:296–304.CrossRefGoogle ScholarPubMed
Kopin, I., Mccarty, R., Torda, T. and Yamaguchi, I. (1980). Catecholamines in plasma and response to stress. In: Catecholamines and Stress: recent advances. Usdin, Koetnansky and Kopin, editors. Elsevier North Holland, pp. 197–204.Google Scholar
Kuchel, O., Buu, N.T., Unger, T. and Genest, J. (1978). Free and conjugated catecholamines in human hypertension. Clin. Sci. Mol. Med. 55 (Suppl 4): 77S–80S.Google Scholar
Lake, C.R., Ziegler, M., Coleman, M. and Kopin, I.J. (1980). Effect of clonidine on sympathetic nervous system function in hypertensive patients (abs). The Pharmacologist 20: 3.Google Scholar
Laks, M.M., Morady, F. and Swan, H. J.C. (1973). Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 65: 75–78.CrossRefGoogle Scholar
Ledda, F., Marchetti, P. and Mucelli, A. (1975). Studies on the positive inotropic effect of phenylephrine: a comparison with isoprenaline. Br. J. Pharmacol. 54:83–90.CrossRefGoogle ScholarPubMed
Loiseau, J. (1938). Les troubles cardiaques dans la maladie de Friedreich. Thèse, Paris.Google Scholar
Lorell, B.H., Paulus, W.J., Grossman, W., Wynne, J. and Cohn, P.F. (1982). Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation 65: 499–507.CrossRefGoogle ScholarPubMed
Lossnitzer, K., Janke, J., Hein, B., Stauch, M. and Fleckenstein, A. (1975). Disturbed myocardial calcium metabolism: a possible pathogenetic factor in the hereditary cardiomyopathy of the Syrian hamster. In: Recent Advances in Studies on Cardiac Structure and Metabolism. Fleckenstein, A. and Rona, G., editors. University Park Press, Baltimore. Vol.6.Google Scholar
Mallani, A., Recordati, G. and Schwartz, P.J. (1973). Nervous activity of afferent cardiac sympathetic fibers with atrial and ventricular endings. J. Physiol. (London) 229: 457–469.CrossRefGoogle Scholar
Micalizzi, E.R. and Pals, D.T. (1979). Evaluation of plasma norepinephrine as an index of sympathetic neuron function in the conscious, unstrained rat. Life Sci. 24: 2071–2076.CrossRefGoogle Scholar
Ostman-Smith, I. (1976). Prevention of exercise-induced cardiac hypertrophy in rats by chemical sympathectomy (guanethidine treatment). Neuroscience 1: 497–507.CrossRefGoogle ScholarPubMed
Ostman-Smith, I. (1979). Adaptive changes in the sympathetic nervous system and some effector organs of the rat following long-term exercise or cold acclimation and the role of cardiac sympathetic nerves in the genesis of compensatory hypertrophy. Acta Physiol. Scand. Suppl. 477: 1–118.Google ScholarPubMed
Ostman-Smith, I. (1981). Cardiac sympathetic nerves as the final common pathway in the induction of adaptive cardiac hypertrophy. Clin. Sci. 61: 265–272.CrossRefGoogle ScholarPubMed
Pasternac, A., Król, R., Petitclerc, R., Harvey, C., Andermann, E. and Barbeau, A. (1980). Hypertrophic cardiomyopathy in Friedreich’s ataxia: symmetric or asymmetric? Can. J. Neurol. Sci. 7:379–382.CrossRefGoogle ScholarPubMed
Pasternac, A., Noble, J., Streulens, Y., Elie, R., Henschke, C. and Bourassa, M.G. (1982). Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries. Circulation 65: 201–213.CrossRefGoogle ScholarPubMed
Perloff, J.K. (1981). Pathogenesis of hypertrophic cardiomyopathy: hypotheses and speculation. Am. Heart J. 101: 219–226.CrossRefGoogle Scholar
Peuler, J.D. and Johnson, G.A. (1977). Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci. 21: 625–636.CrossRefGoogle ScholarPubMed
Pourcher, E. and Barbeau, A. (1980). Field testing of an ataxia scoring and staging system. J. Can. Neurol. Sci. 7: 339–344.CrossRefGoogle ScholarPubMed
Rosing, D.R., Kent, K.M., Borer, J.S., Seides, S.F., Maron, B.J. and Epstein, S.E. (1979). Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 60: 1201–1207.CrossRefGoogle Scholar
Sauebier, I. and Von Mayers Bach, H. (1977). Circadian variation of catecholamines in human blood. Horm. Metab. Res. 9: 529–530.CrossRefGoogle Scholar
Silverberg, A.B., Shah, S.D., Haymond, M.W. and Cryer, P.E. (1978). Norepinephrine: hormone and neurotransmitter in man. Am. J. Physiol. 234: E252–E256.Google ScholarPubMed
Sole, M.J., Wurtman, R.J., Lo, C.M., Kamble, A.B. and Sonnenblick, E.H. (1977). Tyrosine hydroxylase activity in the heart of the cardiomyopathic Syrian hamster. J. Mol. Cell. Cardiol. 9: 225–233.CrossRefGoogle ScholarPubMed
St-John Sutton, M.G.. Olukotun, A.Y., Tajik, A.J., Lovett, J.L. and Giuliani, A. (1980). Left ventricular function in Friedreich’s ataxia. Br. Heart J. 44:309–316.CrossRefGoogle Scholar
Stanton, H.C., Brenner, G. and Mayfield, E.D. (1969). Studies on isoproterenol-induced cardiomegaly in rats. Am. Heart J. 77: 72–80.CrossRefGoogle ScholarPubMed
Thoren, C. (1964). Cardiomyopathy in Friedreich’s ataxia: with studies of cardiovascular and respiratory functions. Acta Paediat. 53 (Suppl 153): 3–136.CrossRefGoogle Scholar
Vaughan Williams, E.M., Raine, A.E.G., Cabrera, A.A., and Whyte, J.M. (1975). The effects of prolonged β-adrenoreceptor blockade on heart weight and cardiac intracellular potentials in rabbits. Cardiovasc. Res. 9: 579–592.CrossRefGoogle Scholar
Williams, L.T., Snyderman, R. and Lefkowitz, R.J. (1976). Identification of β-adrenergic receptors in human lymphocytes by (-) [3H] alprenolol binding. J. Clin. Invest. 57: 149–155.CrossRefGoogle ScholarPubMed